Lumos Pharma, Inc.(NASDAQ : NLNK)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||-0.16%||69.56||1.0%||$505.86m|
|REGN||Regeneron Pharmaceuticals, Inc.||0.18%||635.16||2.7%||$472.48m|
|VRTX||Vertex Pharmaceuticals, Inc.||-0.31%||203.81||1.9%||$464.56m|
|SNSS||Sunesis Pharmaceuticals, Inc.||-4.21%||4.10||0.7%||$286.61m|
|EXAS||EXACT Sciences Corp.||-4.94%||76.59||18.0%||$140.15m|
Lumos Pharma, Inc. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Austin, TX.